FOLFIRI化疗方案联合参芪扶正注射液治疗晚期胃癌的疗效(1)
[摘要] 目的 研究FOLFIRI化疗方案联合参芪扶正注射液治疗晚期胃癌的临床疗效。 方法 选择我院2017年9月～2019年2月内的晚期胃癌患者57例展开研究，按治疗模式不同分为对照组(FOLFIRI化疗方案治疗)和观察组(FOLFIRI化疗方案联合参芪扶正注射液治疗);比较临床疗效、治疗前后患者肿瘤标志物以及免疫功能改善情况。 结果 观察组总有效率为96.5%，对照组为78.5%，差异有统计学意义(P<0.05)。治疗后观察组肿瘤标志物均较对照组低，CD4+和CD4+/CD8+较对照组高，CD8+较对照组低，差异有统计学意义(P<0.05)。 结论 治疗晚期胃癌患者，实施FOLFIRI化疗方案联合参芪扶正注射液疗效显著，可整体提高临床疗效的同时降低用药后的不良反应，并能全面改善患者生活质量，可借鉴并推广。
[关键词] 参芪扶正注射液;晚期胃癌;FOLFIRI化疗方案;肿瘤标志物;免疫功能
[中图分类号] R735.2 [文献标识码] B [文章编号] 1673-9701(2019)24-0083-03
[Abstract] Objective To study the clinical efficacy of FOLFIRI chemotherapy combined with Shenqi Fuzheng injection in the treatment of patients with advanced gastric cancer. Methods A total of 57 patients with advanced gastric cancer from September 2017 to February 2019 in our hospital were selected for the study. According to different treatment modes， they were divided into control group(FOLFIRI chemotherapy regimen) and observation group(FOLFIRI chemotherapy regimen combined with Shenqi Fuzheng injection); the clinical efficacy， tumor markers and immune function improvement before and after treatment were compared. Results The efficacy in the observation group was 96.5%， and that in the control group was 78.5%. The difference was statistically significant(P<0.05). After treatment， the tumor markers in the observation group were lower than those in the control group， CD4+ and CD4+/CD8+ were higher than those in the control group， and CD8+ was lower than that in the control group(P<0.05). Conclusion In the treatment of patients with advanced gastric cancer， the efficacy of FOLFIRI chemotherapy combined with Shenqi Fuzheng injection is significant. It can improve the clinical efficacy as a whole while reducing the adverse reactions after medication， and can comprehensively improve the quality of life of patients， which can be used for reference and promotion.
[Key words] Shenqi Fuzheng injection; Advanced gastric cancer; FOLFIRI chemotherapy regimen; Tumor markers; Immune function
胃癌屬于临床最常见的恶性肿瘤，并且近年来在各种内外因素的共同推动下，致使我国胃癌患者人数逐年攀升;经研究证明胃癌主要发病于胃黏膜上皮部位，对患者身体健康和生命安全造成严重威胁。胃癌患者早期并无明显的临床症状，而随着疾病的进一步发展，绝大多数患者出现不同程度的恶心、呕吐等一系列上消化道症状，所以才被逐渐引起重视。而绝大多数患者在确诊时就已经发展至胃癌晚期，因此错过了手术治疗的最佳时机。化疗是现阶段我国治疗晚期癌症患者最常用的重要手段，通过化疗方案可有效杀伤癌症患者体内的肿瘤细胞，但不可否认，同时会对正常的细胞造成一定的损伤，从而致使临床疗效大打折扣。但近年来随着中西医结合治疗方案的不断发展，我国基层医院在治疗晚期癌症患者中采用中西医结合的方式，不仅可以提高临床疗效，还能整体改善患者预后情况[1-2]。经调查研究发现，参芪扶正注射液主要有党参和黄芪的提取物，所以在增强患者机体免疫功能方面有着其他药物无法比拟的优势，所以本研究中选取我院胃癌患者57例，分别实施两种治疗措施，现报道如下。, http://www.100md.com(唐惠华 黄黎)
[关键词] 参芪扶正注射液;晚期胃癌;FOLFIRI化疗方案;肿瘤标志物;免疫功能
[中图分类号] R735.2 [文献标识码] B [文章编号] 1673-9701(2019)24-0083-03
[Abstract] Objective To study the clinical efficacy of FOLFIRI chemotherapy combined with Shenqi Fuzheng injection in the treatment of patients with advanced gastric cancer. Methods A total of 57 patients with advanced gastric cancer from September 2017 to February 2019 in our hospital were selected for the study. According to different treatment modes， they were divided into control group(FOLFIRI chemotherapy regimen) and observation group(FOLFIRI chemotherapy regimen combined with Shenqi Fuzheng injection); the clinical efficacy， tumor markers and immune function improvement before and after treatment were compared. Results The efficacy in the observation group was 96.5%， and that in the control group was 78.5%. The difference was statistically significant(P<0.05). After treatment， the tumor markers in the observation group were lower than those in the control group， CD4+ and CD4+/CD8+ were higher than those in the control group， and CD8+ was lower than that in the control group(P<0.05). Conclusion In the treatment of patients with advanced gastric cancer， the efficacy of FOLFIRI chemotherapy combined with Shenqi Fuzheng injection is significant. It can improve the clinical efficacy as a whole while reducing the adverse reactions after medication， and can comprehensively improve the quality of life of patients， which can be used for reference and promotion.
[Key words] Shenqi Fuzheng injection; Advanced gastric cancer; FOLFIRI chemotherapy regimen; Tumor markers; Immune function
胃癌屬于临床最常见的恶性肿瘤，并且近年来在各种内外因素的共同推动下，致使我国胃癌患者人数逐年攀升;经研究证明胃癌主要发病于胃黏膜上皮部位，对患者身体健康和生命安全造成严重威胁。胃癌患者早期并无明显的临床症状，而随着疾病的进一步发展，绝大多数患者出现不同程度的恶心、呕吐等一系列上消化道症状，所以才被逐渐引起重视。而绝大多数患者在确诊时就已经发展至胃癌晚期，因此错过了手术治疗的最佳时机。化疗是现阶段我国治疗晚期癌症患者最常用的重要手段，通过化疗方案可有效杀伤癌症患者体内的肿瘤细胞，但不可否认，同时会对正常的细胞造成一定的损伤，从而致使临床疗效大打折扣。但近年来随着中西医结合治疗方案的不断发展，我国基层医院在治疗晚期癌症患者中采用中西医结合的方式，不仅可以提高临床疗效，还能整体改善患者预后情况[1-2]。经调查研究发现，参芪扶正注射液主要有党参和黄芪的提取物，所以在增强患者机体免疫功能方面有着其他药物无法比拟的优势，所以本研究中选取我院胃癌患者57例，分别实施两种治疗措施，现报道如下。, http://www.100md.com(唐惠华 黄黎)